Cytogenetic and Genome Research
Gene Mapping, Cloning, and Sequencing
Chromosomal mapping of the human genes CKS1 to 8q21 and CKS2 to 9q22Demetrick D.J. · Zhang H. · Beach D.H.Cold Spring Harbor Laboratory and Howard Hughes Medical Institute, Cold Spring Harbor, NY (USA)
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Accepted: July 19, 1995
Published online: May 20, 2008
Issue release date: 1996
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)
For additional information: https://www.karger.com/CGR
Abstract
The human cdk2/cyclin A kinase complex is a key regulator of the events of S phase. This complex contains several proteins involved in regulating its catalytic activity, including one or more of the CKS proteins, which have recently been shown to inhibit the activation of the cdk2 kinase. To investigate whether the CKS genes may be altered in human neoplasia, we mapped the chromosome locations of CKS 1 and CKS2 by fluorescence in situ hybridization (FISH). CKS1 was localized to 8q21, a locus that is seldom grossly altered in cancer. The localization of CKS2to 9q22 places it very near to a putative tumour suppressor locus suggested to be responsible for susceptibility to the Basal Cell Nevus Syndrome (BCNS or Gorlin’s syndrome) familial cancer disorder. Six fibroblast cell lines isolated from patients with BCNS were demonstrated by FISH to have both copies of CKS2 present. Partial sequencing of a genomic clone of CKS2 revealed that the open reading frame lies over three exons. Examination of the six cell lines by SSCP and PCR-based sequencing of the parts of the three exons coding for the full length protein demonstrated no consistent divergence from the reported cDNA sequence in any exon. It is unlikely that CKS2 is the BCNS tumour suppressor gene.
© 1996 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Accepted: July 19, 1995
Published online: May 20, 2008
Issue release date: 1996
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)
For additional information: https://www.karger.com/CGR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission